Jöerg Schubert

2.2k total citations
28 papers, 283 citations indexed

About

Jöerg Schubert is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Jöerg Schubert has authored 28 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 11 papers in Genetics and 9 papers in Immunology. Recurrent topics in Jöerg Schubert's work include Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Complement system in diseases (4 papers). Jöerg Schubert is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Complement system in diseases (4 papers). Jöerg Schubert collaborates with scholars based in Germany, Italy and France. Jöerg Schubert's co-authors include Kimmo Linnavuori, Benedikt Weißbrich, Klaus Hedman, Heikki Peltola, Lea Hedman, Michael Pfreundschuh, P. Dědič, Marcel Reiser, Matthias Peipp and Christian Kellner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jöerg Schubert

28 papers receiving 275 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jöerg Schubert Germany 8 125 68 64 62 46 28 283
Masahiro Yasui Japan 12 145 1.2× 122 1.8× 47 0.7× 58 0.9× 86 1.9× 40 404
Yuichiro Nawa Japan 10 101 0.8× 49 0.7× 70 1.1× 88 1.4× 145 3.2× 32 337
Smeeta Gajendra India 10 54 0.4× 36 0.5× 53 0.8× 50 0.8× 88 1.9× 52 261
Ioannis Baltadakis Greece 9 77 0.6× 56 0.8× 22 0.3× 34 0.5× 98 2.1× 17 232
Takayuki Tabayashi Japan 12 100 0.8× 65 1.0× 74 1.2× 46 0.7× 108 2.3× 43 365
Sushrut Patil Australia 10 66 0.5× 37 0.5× 81 1.3× 60 1.0× 98 2.1× 35 292
Emilia Jaskuła Poland 11 109 0.9× 116 1.7× 91 1.4× 28 0.5× 96 2.1× 27 285
J Maertens Belgium 7 112 0.9× 30 0.4× 56 0.9× 102 1.6× 65 1.4× 10 250
Reiki Ogasawara Japan 9 69 0.6× 95 1.4× 29 0.5× 29 0.5× 119 2.6× 27 293
Maria Pletneva United States 9 121 1.0× 192 2.8× 60 0.9× 37 0.6× 88 1.9× 22 420

Countries citing papers authored by Jöerg Schubert

Since Specialization
Citations

This map shows the geographic impact of Jöerg Schubert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jöerg Schubert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jöerg Schubert more than expected).

Fields of papers citing papers by Jöerg Schubert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jöerg Schubert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jöerg Schubert. The network helps show where Jöerg Schubert may publish in the future.

Co-authorship network of co-authors of Jöerg Schubert

This figure shows the co-authorship network connecting the top 25 collaborators of Jöerg Schubert. A scholar is included among the top collaborators of Jöerg Schubert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jöerg Schubert. Jöerg Schubert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kobsar, Anna, et al.. (2023). Composition of plasma in apheresis-derived platelet concentrates under cold storage.. PubMed. 21(4). 327–336. 1 indexed citations
2.
Pellissier, Vincent, Sebastian König, Sven Hohenstein, et al.. (2021). SARS-CoV-2 rapid antigen testing in the healthcare sector: A clinical prediction model for identifying false negative results. International Journal of Infectious Diseases. 112. 117–123. 3 indexed citations
3.
Fasching, Peter A., Eva‐Maria Grischke, Florian Schuetz, et al.. (2017). Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.. Journal of Clinical Oncology. 35(15_suppl). 1061–1061. 3 indexed citations
4.
Chevallier, Patrice, Myriam Labopin, Stefanie Buchholz, et al.. (2012). Clofarabine‐containing conditioning regimen for allo‐SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. European Journal Of Haematology. 89(3). 214–219. 17 indexed citations
5.
Held, Gerhard, Niels Murawski, Marita Ziepert, et al.. (2012). Role of radiotherapy for elderly DLBCL patients in the rituximab (R) era: Final results of the RICOVER-60-no-rx study of the DSHNHL.. Journal of Clinical Oncology. 30(15_suppl). 8022–8022. 1 indexed citations
6.
Kellner, Christian, Joerg Bruenke, Jöerg Schubert, et al.. (2011). Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Letters. 303(2). 128–139. 39 indexed citations
7.
Hehlmann, Rüdiger, Michael Lauseker, Susanne Jung-Munkwitz, et al.. (2010). Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV.. Journal of Clinical Oncology. 28(15_suppl). 6517–6517. 5 indexed citations
8.
Zwick, Carsten, Klaus‐Dieter Preuss, Boris Kubuschok, et al.. (2009). Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens. Annals of Hematology. 88(10). 999–1003. 3 indexed citations
9.
Glaß, Bertram, Justin Hasenkamp, Peter Dreger, et al.. (2009). Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.. Blood. 114(22). 3379–3379. 4 indexed citations
10.
Fletcher, John D., et al.. (2009). Potato virus Y Strain Spectrum in New Zealand – Absence of Recombinant N:O Strains. Journal of Phytopathology. 157(7-8). 507–510. 9 indexed citations
11.
Kelly, Richard, Louise Arnold, Stephen J. Richards, et al.. (2008). Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment. Blood. 112(11). 4576–4576. 4 indexed citations
12.
13.
14.
15.
Bittenbring, Joerg Thomas, Manfred Ahlgrimm, Markus Ditschkowski, et al.. (2008). Identification of New Minor Histocompatibility Antigens (mHags) in Patients with Chronic Graft Versus Host Disease (GvH) after Allogeneic Stem Cell Transplantation by SEREX.. Blood. 112(11). 2198–2198. 1 indexed citations
16.
Schmidt‐Wolf, Ingo, Thomas Moehler, Hartmut Goldschmidt, et al.. (2006). Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.. Blood. 108(11). 3559–3559. 1 indexed citations
17.
Held, Gerhard, Jöerg Schubert, Marcel Reiser, & Michael Pfreundschuh. (2006). Dose-Intensified Treatment of Advanced-Stage Diffuse Large B-Cell Lymphomas. Seminars in Hematology. 43(4). 221–229. 11 indexed citations
18.
Junker, Kerstin, et al.. (1999). Genetic characterization of multifocal tumor growth in renal cell carcinoma. Kidney International. 56(4). 1291–1294. 3 indexed citations
19.
Linnavuori, Kimmo, Heikki Peltola, Benedikt Weißbrich, et al.. (1998). Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. Journal of Medical Virology. 56(3). 186–191. 102 indexed citations
20.
Linnavuori, Kimmo, et al.. (1998). Immunoreactivation of Epstein‐Barr virus due to cytomegalovirus primary infection. Journal of Medical Virology. 56(3). 186–191. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masahiro Yasui Breakdown of academic impact, for papers by Yuichiro Nawa Breakdown of academic impact, for papers by Smeeta Gajendra Breakdown of academic impact, for papers by Ioannis Baltadakis Breakdown of academic impact, for papers by Takayuki Tabayashi Breakdown of academic impact, for papers by Sushrut Patil Breakdown of academic impact, for papers by Emilia Jaskuła Breakdown of academic impact, for papers by J Maertens Breakdown of academic impact, for papers by Reiki Ogasawara Breakdown of academic impact, for papers by Maria Pletneva
Rankless by CCL
2026